Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 19, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

[Small-cell lung cancer].

Fabrice Barlesi1

  • 1Service d'oncologie thoracique, EA3279, Université de la Méditerranée Assistance publique - hôpitaux de Marseille, 13274 Marseille Cedex 09. fabrice.barlesi@mail.ap-hm.fr

La Revue Du Praticien
|October 21, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Molecular cancer·2026
Same author

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
Same author

Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?

Cancer·2026
Same author

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Small-cell lung cancer (SCLC) is a common form of lung cancer. Current standard treatments include chemotherapy with cisplatin and etoposide, thoracic radiotherapy for limited disease, and prophylactic cranial irradiation.

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Imaging

Context:

  • Small-cell lung cancer (SCLC) accounts for 10-15% of all lung cancers.
  • SCLC has a decreasing incidence but is known for frequent paraneoplastic syndromes.
  • Diagnosis relies on computed tomography (CT) scans of the chest, abdomen, and brain.

Purpose:

  • To outline the current diagnostic and treatment standards for small-cell lung cancer.
  • To detail the established chemotherapy regimens, radiotherapy protocols, and prophylactic cranial irradiation guidelines.
  • To provide an overview of second-line treatment options for SCLC.

Summary:

  • The standard first-line treatment for SCLC involves intravenous chemotherapy with cisplatin and etoposide for 6 cycles.
  • Thoracic radiotherapy (≥45 grays) is standard for limited-stage SCLC.

Related Experiment Videos

Last Updated: Jun 19, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

  • Prophylactic cranial irradiation is recommended for limited-stage SCLC and considered for disseminated disease responders.

    • Impact:

    • Establishes the current benchmarks for SCLC management.
    • Informs clinical decision-making for oncologists and pulmonologists.
    • Provides a concise reference for SCLC diagnostic work-up and therapeutic strategies.